Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.72 |
| ▸ | AURKA | O14965 | 7/20 | 0.68 |
| ▸ | ABL1 | P00519 | 7/20 | 0.68 |
| ▸ | LCK | P06239 | 7/20 | 0.68 |
| ▸ | FYN | P06241 | 7/20 | 0.68 |
| ▸ | CSF1R | P07333 | 7/20 | 0.68 |
| ▸ | MET | P08581 | 7/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.68 |
| ▸ | FLT1 | P17948 | 7/20 | 0.68 |
| ▸ | FLT3 | P36888 | 7/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.68 |
| ▸ | NTRK2 | Q16620 | 7/20 | 0.68 |
| ▸ | BLK | P51451 | 6/20 | 0.68 |
| ▸ | STK3 | Q13188 | 6/20 | 0.68 |
| ▸ | NEK2 | P51955 | 6/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.68 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.68 |
| ▸ | MAP4K2 | Q12851 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528845 | 0.94 | KDR (0.72) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3534816 | 0.91 | KDR (0.69) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3528322 | 0.91 | KDR (0.69) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3528015 | 0.91 | KDR (0.68) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3524653 | 0.91 | KDR (0.69) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3525442 | 0.90 | KDR (0.65) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3531798 | 0.89 | KDR (0.70) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3530647 | 0.85 | KDR (0.83) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3528491 | 0.85 | KDR (0.83) | KDRAURKBAURKAABL1LCK | |
| SCHEMBL3524767 | 0.85 | KDR (0.67) | KDRAURKBAURKAABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740458-B1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP GES FÜR MAN MBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| EP-2740458-A1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP Gesellschaft für Management mbH (DE) | 2014-06-11 | — | — | EP | disclosed |
| US-8436179-B2 | Kinase inhibitor with improved solubility profile | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2013012909-A1 | KINASE INHIBITOR WITH IMPROVED AQUEOUS SOLUBILITY | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130023555-A1 | KINASE INHIBITOR WITH IMPROVED SOLUBILITY PROFILE | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885AURKB 171/4885AURKA 207/4885 |
| US-20130023555-A1 | KINASE INHIBITOR WITH IMPROVED SOLUBILITY PROFILE | AURKC, AURKA, FLT4 | KDR 12/4885AURKB 6/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.